DUBLIN--(BUSINESS WIRE)--The "Anaphylaxis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Anaphylaxis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Companies Mentioned
- Aquestive Therapeutics
- Insys Therapeutics Inc
- MannKind Corp
- Merck & Co Inc
- Shenox Pharmaceuticals LLC
Key Topics Covered
- Introduction
- Report Coverage
- Anaphylaxis - Overview
- Anaphylaxis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Anaphylaxis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anaphylaxis - Companies Involved in Therapeutics Development
- Aquestive Therapeutics
- Insys Therapeutics Inc
- MannKind Corp
- Merck & Co Inc
- Shenox Pharmaceuticals LLC
- Anaphylaxis - Drug Profiles
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- epinephrine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SHX-008 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- XL-499 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Anaphylaxis - Dormant Projects
- Anaphylaxis - Product Development Milestones
- Featured News & Press Releases
For more information about this report visit https://www.researchandmarkets.com/research/t24hc4/anaphylaxis?w=4
